WO2008010527A1 - Composition laxative - Google Patents

Composition laxative Download PDF

Info

Publication number
WO2008010527A1
WO2008010527A1 PCT/JP2007/064205 JP2007064205W WO2008010527A1 WO 2008010527 A1 WO2008010527 A1 WO 2008010527A1 JP 2007064205 W JP2007064205 W JP 2007064205W WO 2008010527 A1 WO2008010527 A1 WO 2008010527A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
glutamic acid
food
nucleotide
nutrient
Prior art date
Application number
PCT/JP2007/064205
Other languages
English (en)
Japanese (ja)
Inventor
Shinji Somekawa
Mio Fujimaki
Naoki Hayashi
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Priority to JP2008525888A priority Critical patent/JP5412830B2/ja
Publication of WO2008010527A1 publication Critical patent/WO2008010527A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • composition for improving bowel movement Composition for improving bowel movement
  • the present invention relates to a composition effective for preventing or improving bowel movement abnormalities.
  • the composition is used as a medicine or food.
  • Non-patent Document 1 High-viscosity and / or aqueous solutions and nutrients may be used for the purpose of preventing aspiration diarrhea, but this may make bowel movement abnormal due to the extension of gastric stagnation time due to increased liquid viscosity It is reported that constipation worsens (Non-patent Document 1).
  • Non-patent document 1 Jiro Kanie, “Nursing of gastrostomy PEG complications and practice of solidified nutrition” 2004, 125-132, 162-163 Disclosure of the invention
  • An object of the present invention is to provide a composition effective in preventing or improving bowel movement abnormalities.
  • the present inventors have found that glutamic acid or a derivative thereof, or 5′-nucleotide has an effect of improving abnormal bowel movement, and have completed the present invention.
  • the present invention provides the following.
  • a composition for improving bowel movement comprising at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotide.
  • Viscosity at 25 ° is in the range of 40011 11 ⁇ 2 '3-10, OOOmPa's, [1] or [2
  • composition according to any one of [1] to [3], which is used in combination with a nutrient is used in combination with a nutrient.
  • composition according to any one of [1] to [3] for use in combination with a nutrient is provided.
  • composition according to any one of [1] to [8], which is a pharmaceutical product is a pharmaceutical product.
  • composition according to [12], wherein the functional health food is a food for specified health use or a functional food for nutrition.
  • a method for preventing or improving bowel movement abnormalities comprising containing at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotide as an active ingredient, and administering an effective amount thereof to a subject.
  • composition for improving bowel movement is used in combination with a high-viscosity composition in the range of 10, OOmPa ⁇ s at 25 ° C; ] Use according to any one of the above.
  • a bowel movement improving agent comprising at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotide.
  • the composition for improving bowel movements of the present invention is effective in preventing or improving excellent bowel movement abnormalities.
  • it is useful for improving bowel movement caused by transesophageal, gastric or enteral nutrition.
  • the composition of the present invention contains at least one member selected from the group consisting of glutamic acid and its derivatives and 5′-nucleotide as an active ingredient, it has very little harmful reaction.
  • it has the advantage that it does not cause rapid constipation, abdominal pain, diarrhea, etc. as seen when taking laxatives.
  • FIG. 1 is a graph showing the proportion of defecation accumulated for each individual.
  • FIG. 2 is a graph showing the proportion of individuals who defecate.
  • the present invention is a group consisting of glutamic acid and derivatives thereof, and 5'-nucleotide.
  • a composition for improving bowel movements comprising at least one selected from the group consisting of:
  • “improvement of bowel movement” means prevention of onset of abnormal bowel movement or improvement of abnormal bowel movement (for example, prevention or improvement of bowel movement), for example, without causing diarrhea (that is, normal bowel movement or In a loose stool state), preferably refers to regular stable defecation. Therefore, “improvement of bowel movement” in the present invention includes prevention of abnormal bowel movement.
  • the bowel movement abnormality is caused by the following causes, for example.
  • Constipation that occurs when gastrostomy / enteral tube feeding method is applied by injecting liquid nutrients into the digestive tract via a tube placed with an external fistula (fistula) in the esophagus, stomach, or jejunum .
  • glutamic acid can be any of L-integral, D-isomer, and DL-isomer, preferably L-integral and DL-isomer, and more preferably L-integral. In the present invention, any of these cases is included in the present invention.
  • glutamic acid is a concept including salts thereof, and embodiments of the salts are also included in the present invention. In this specification, these are collectively referred to as “glutamic acid”!
  • the derivative of glutamic acid may be glutamic acid as long as it is capable of exhibiting the desired effect of the present invention as glutamic acid by in vivo metabolism, for example, by hydrolysis in vivo. It is a concept that includes a salt as well. Examples thereof include dipeptides and tripeptides containing glutamic acid, and polymers containing glutamic acid as a main component. Examples of such derivatives are as follows.
  • 5 ′ nucleotides include 5 ′ inosinic acid, 5′-guanylic acid, 5′-adenylic acid, 5′-cytidylic acid, 5′-uridylic acid, and 5′-xanthylic acid, Of these, 5'-inosinic acid and 5'-guanylic acid are preferred. In the present invention, any of these cases is included in the present invention. And 5'-nucleotide is The concept includes salts thereof, and embodiments of the salts are also included in the present invention. In the present specification, these are collectively referred to as “5′-nucleotide”! /.
  • the present invention also includes glutamic acid or a derivative thereof, or a salt of 5'-nucleotide, and the term "salt" refers to a salt with an inorganic base and a salt with an organic acid.
  • the salt with an inorganic base include alkali metal salts such as sodium, potassium and lithium, alkaline earth metal salts such as calcium and magnesium, and ammonium salts.
  • the salt with inorganic acid include salts with hydrohalic acid (hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid and the like.
  • salt with organic acid examples include salts with formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, citrate, glutamic acid, aspartic acid, histidine and the like.
  • alkali metal salts such as sodium salts are preferred.
  • the content of 5,1 nucleotide is preferably 0.05-2.0% by weight, more preferably 0.;! ⁇ 1.8% by weight as free 5,1 nucleotide.
  • the weight% of the glutamic acid derivative is the amount of free glutamic acid produced by hydrolyzing the derivative. If the content is within this numerical range, an excellent bowel movement improving effect that causes an adverse reaction can be exhibited.
  • the composition of the present invention is useful as a medicine, food and drink, etc.
  • the administration target thereof is a mammal (eg, human, mouse, rat, mouse, muster, usagi, cat, inu, ushi, Higgies and monkeys).
  • the dose (intake) of the composition may be appropriately adjusted according to the body weight or size of the animal.
  • the administration form of the composition of the present invention is not particularly limited, but general administration such as oral administration, transesophageal administration, gastric administration, or enteral administration (enteral administration, rectal administration, or jejunal administration), etc. You can go through the route.
  • the dosage form includes general pharmaceutical preparations such as tablets (eg, sugar-coated tablets and film-coated tablets), pills, capsules, sachets, suspensions, solutions, syrups, gam preparations, drops preparations and powders.
  • the mold can be adopted
  • the composition of the present invention is preferably used in combination with a nutrient because it suppresses constipation that occurs during enteral administration, for example.
  • enteral administration or the like is performed as a preparation mixed with the nutrient or as a preparation separate from the nutrient.
  • the composition of the present invention suppresses constipation or the like that occurs during high-viscosity compositions (such as high-viscosity aqueous solutions and high-viscosity nutrients), for example, during enteral administration. It is preferable to use together with the product.
  • enteral administration for example, as a preparation blended with a high-viscosity composition or as a preparation separate from the high-viscosity composition.
  • enteral administration has been described, but the same applies to oral and gastric administration.
  • Preparation of the preparation is carried out by formulating it by a conventional method.
  • various pharmacologically acceptable pharmaceutical substances can be added as necessary.
  • the substance for the preparation can be appropriately selected depending on the dosage form of the preparation.
  • the excipient, the diluent, the disintegrant, the binder, the coating agent, the lubricant, the lubricant, the lubricant, the flavor, and the sweetener. Solubilizers, thickeners and the like.
  • pharmaceutical substances include magnesium carbonate, titanium dioxide, ratatoose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils, polyethylene glycol, and solvents.
  • sterilized water and mono- or polyhydric alcohols such as glycerol.
  • composition of the present invention examples include solid, powder, liquid, and semisolid.
  • semisolid for tube feeding, a liquid or semi-solid form is preferred.
  • the content of glutamic acid or a derivative thereof or 5'-nucleotide in the preparation is preferably 0.01 g to 20 g as a free gnoretamic acid and 0.01 g to 20 g as a free 5'-nucleotide.
  • the dose varies depending on the age, weight or disease state, dosage form, or administration method of the subject patient.
  • Daily dosages of glutamic acid or its derivatives, or 5'-nucleotide are generally 0.01 g to 20 g as free glutamic acid and 0.01 g to 20 g as free 5'-nucleotide.
  • the daily dose of dartamic acid or a derivative thereof, or 5′-nucleotide be adjusted with free glutamic acid. Then, 0.01 g to 20 g, more preferably 0.1 lg to;!
  • the daily dose can be administered at once or in several divided doses (eg 3 times).
  • the timing of administration does not matter before meals, after meals, and between meals.
  • the administration period is not particularly limited.
  • composition for improving bowel movements of the present invention may be administered alone, or may be administered in combination with a nutrient such as a transesophageal nutrient, a gastric nutrient, and an enteral nutrient.
  • a nutrient such as a transesophageal nutrient, a gastric nutrient, and an enteral nutrient.
  • it When administered in combination with a nutrient, it may be formulated in a nutrient or separately.
  • the route of administration and dosage form may be the same or different, and the timing of administration of each may be simultaneous or separate. Good.
  • the transesophageal, gastro and enteral nutrients used in combination with the present invention are originally used for efficient nutritional supplementation, so the ingredients used are purified raw materials with very good digestion and absorption.
  • the gastrointestinal tract has a low residue. Therefore, constipation occurs at a high rate in patients with inactive gastrointestinal motility, especially in the elderly, because there is no stool stimulation due to insufficient stool volume. This is a serious problem not only for patients but also for healthcare workers and caregivers. In this treatment, laxatives and bowel regulators are administered.
  • the product of the present invention it is possible to prevent abnormalities of defecation of these nutritional supplement users and to save the cost of laxatives and intestinal preparations.
  • the composition for improving bowel movements of the present invention can be used together with conventionally known nutrients that cause abnormal bowel movements.
  • the nutrient is a nutritional composition containing at least one nutrient of protein, carbohydrate, and lipid. More specifically, proteins (casein as animal protein, milk protein such as salt and whey, fish protein, egg protein, and soy protein, wheat protein, and corn protein as vegetable protein, etc.) Including raw materials processed into powder, granules, flakes or pellets), sugars (such as glucose and fructose), disaccharides (such as sucrose, lactose, and maltose), and polysaccharides (starch, As well as fat (animal fat or vegetable fat), various amino acids (excluding glutamic acid), vitamins (such as fat-soluble vitamins and water-soluble vitamins), and minerals (calcium, magnesium, etc.) Potassium, sub For example, lead or iron).
  • the composition of nutrients is protein, carbohydrate, and fat, but is not
  • the high calorie and high protein nutrient means a protein content of, for example, 5 to 15 mass%, particularly 7 to 14 mass%. Even when the calorific value is 1.5-2. 2 kcal / g, 40-50 g / day, which is the amount of protein required for elderly people over 70 years old, can be obtained only with the nutrient.
  • at least milk protein or soybean protein is contained. If necessary, a hydrolyzate or amino acid of the protein raw material may be added to supplement the protein.
  • These proteins or protein lysates and lysates can be present in various proportions.
  • the above nutrient may be contained in the composition of the present invention.
  • the dose of the active ingredient varies depending on the age, weight or pathological condition, dosage form, administration method, etc. of the subject patient.
  • the daily dosage of glutamic acid or its derivatives, or 5′-nucleotides is from 0.01 g to 20 g as free glutamic acid and from 0.01 g to 20 g as free 5′-nucleotide.
  • the daily dosage of glutamic acid or a derivative thereof, or 5′-nucleotide is 0.01 g to 20 g as free gnoretamic acid, more preferably from 0. lg to 10 g, and as a free 5, neutral age, 0.01 g to 20 g, more preferably 0.1 lg to 10 g.
  • the daily dose can be administered once or divided into several (eg, 3) doses.
  • the composition of the present invention used in combination with the nutrients specifically includes nutrition management before and after surgery, diseases requiring intestinal cleansing, abnormal gastrointestinal conditions (suture failure, short bowel syndrome, Various types of gastrointestinal hemorrhoids), gastrointestinal tract diseases (Crohn's disease, ulcerative colitis, digestive dysfunction syndrome, hemorrhoids, protein-losing enteropathy, etc.) Used for nutritional management, elderly people with poor digestive capacity, and infants with immature digestive capacity. Further, the composition of the present invention combined with the nutrient is also used for gastrostomy and intestinal fistula patients whose gastrointestinal function is suppressed.
  • the composition of the present invention used in combination with the nutritional agent is, for example, a patient with cerebrovascular disorder or cerebral infarction, which is a disease other than digestive organ disease, It is also suitable for administration of liquid nutrients via gastric fistula and intestinal fistula for patients who are difficult to ingest, such as dementia patients.
  • the composition of the present invention is particularly preferably used for elderly people who have reduced digestive ability. Even more preferably, it is preferably used for patients with gastrostoma and intestinal fistula.
  • the composition of the present invention contains glutamic acid or a derivative thereof, or a nutrient source other than 5'-nucleotide
  • the composition has a calorie of 0.5 to 3. Okcal / g, preferably 1. It is preferable that the concentration is adjusted to about 0 to 2.2 kcal / g.
  • the viscosity of the composition of the present invention is preferably a viscosity at 25 ° C.
  • the composition of the present invention can be easily used in the form of food.
  • the food of the present invention contains glutamic acid and its derivatives, and at least one selected from the group consisting of 5′-nucleotides, and is taken for a specific purpose of “improvement of bowel movement”.
  • the food of the present invention may be a general food including so-called health food.
  • the food of the present invention can be used as a health functional food, a food for specified health use, a nutritional functional food, or a dietary supplement (nutritional supplement) as defined in the Health Functional Food System of the Ministry of Health, Labor and Welfare. Monkey.
  • the food of the present invention may be ingested as it is, but in order to make it easier to ingest, ordinary food materials, seasonings, flavors and the like are added to the composition. It may be processed and ingested into a form such as a drink, gum, powder, tablet, granule, or jelly.
  • a tablet comprising the composition and a disintegrant, a mixture of the composition and a bulking agent (protein hydrolyzate, starch, casein, glucose, etc.), and the composition capable of sustained release in the oral cavity.
  • a mixture of the composition with a sticky agent (gum, sublingual tablet, and troche), a solution of the composition and a solvent in which it is dissolved (eg edible oils, ethanol or water), W / O containing the composition
  • a sticky agent for example, a sticky agent
  • a solution of the composition and a solvent in which it is dissolved eg edible oils, ethanol or water
  • W / O containing the composition eg edible oils, ethanol or water
  • an O / W emulsion, a mixture of the composition and a nutrient eg, protein, amino acid, vitamin, lipid, glucose, etc.
  • the daily intake of glutamic acid or a derivative thereof, or 5'-nucleotide, for adults (with a body weight of 60kg) or 5'-nucleotide is free gnoretamic acid.
  • free 5, 1 nucleotide 0.01 g to 20 g is preferable, 0 ⁇ Olg to 10 kg is more preferable, 0 to 1 g is more preferable.
  • the content of the onset glutamic acid or a derivative light in food or 5'-nucleotides are as free Gunoretamin acid is usually 0.5 05-2. 0 wt 0/0, preferably from 0.1 to 1. 8% by weight, usually as free 5′-nucleotide, 0.05-2.0% by weight, preferably 0.;! ⁇ 1.8% by weight.
  • composition for improving bowel movements comprising at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5'-nucleotides can be used for improving bowel movements.
  • commercial packages that contain statements stating that they should be used. The package applies to both medicine and food.
  • the mixing ratio of each raw material is as shown in Table 1.
  • the preparation method when 4000g is charged is described below. 1420 g of prepared water was weighed in a 5 L stainless steel bucket (hereinafter referred to as “A”) and heated to 70-80 ° C. in a hot water bath. Next, dextrin, granulated sugar, ferrous sodium citrate, sodium phosphate, phosphoric acid under high-speed stirring conditions of 3000 rpm with a high-speed stirrer (product name “TK Robomix”, Special Machine Engineering Co., Ltd.) Potassium, tripotassium citrate, and sodium dalconate were dissolved in this order.
  • A 5 L stainless steel bucket
  • TK Robomix Special Machine Engineering Co., Ltd.
  • the mixing ratio of each raw material is as shown in Table 2.
  • the preparation method when 4000g is charged is described below. 1600 g of prepared water was weighed in a 5 L stainless steel bucket (hereinafter referred to as “B”) and heated to 70-80 ° C. in a hot water bath. Next, dextrin, granulated sugar, water-soluble dietary fiber, ferrous sodium citrate, zinc dalconate under high-speed stirring conditions of 2000 rpm with a high-speed stirrer (product name “TK Robomix”, Tokushu Kika Kogyo Co., Ltd.) , Copper dalconate, sodium phosphate, potassium phosphate, tripotassium citrate, sodium dalconate, and sodium chloride were dissolved in this order.
  • the blending ratio of each raw material is as shown in Table 3.
  • the preparation method when 4000g is charged is described below. 1630 g of prepared water was weighed in a 5 L stainless steel bucket (hereinafter referred to as C) and heated to about 85 ° C in a hot water bath. Next, powder agar was added and dissolved.
  • a 5-week-old male SD rat was fasted overnight, and a stomach fistula was surgically created.
  • the stomach was fixed to the abdominal wall to suppress gastrointestinal motility.
  • the product of the present invention and the composition A (comparative example product) containing only MSG (sodium glutamate) were administered (6 kcal / hour), and the defecation status was determined every hour. Observed until 4 hours later.
  • a thickener (carboxymethylcellulose) was appropriately added to the product of the present invention to prepare a composition having a viscosity value of 2,000 mPa-s, 10,000 mPa-s, or 20, OOOmPa's, respectively.
  • a gastrostomy was prepared in 6-week-old SD male rats, and the stomach was fixed to the abdominal wall to suppress gastrointestinal motility. 9 days after surgery for gastrostoma Each composition was administered 7 times every 1 hour (2.7 mL / 3g / 6k C aV times) in the stomach, and the defecation status was completed once every hour until 1 hour I observed it.
  • a composition having an effect on prevention or improvement of abnormal bowel movement is provided. Since the composition contains at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotides as an active ingredient, it has very little adverse reaction. In particular, it has the advantage that it does not cause rapid constipation, abdominal pain, diarrhea, etc. as seen when taking laxatives.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur une composition laxative plus efficace. La présente invention porte spécifiquement sur une composition laxative qui comprend au moins un élément sélectionné au sein du groupe constitué par l'acide glutamique, l'un de ses dérivés et un nucléotide 5'.
PCT/JP2007/064205 2006-07-18 2007-07-18 Composition laxative WO2008010527A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008525888A JP5412830B2 (ja) 2006-07-18 2007-07-18 便通改善用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006196212 2006-07-18
JP2006-196212 2006-07-18

Publications (1)

Publication Number Publication Date
WO2008010527A1 true WO2008010527A1 (fr) 2008-01-24

Family

ID=38956859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/064205 WO2008010527A1 (fr) 2006-07-18 2007-07-18 Composition laxative

Country Status (2)

Country Link
JP (1) JP5412830B2 (fr)
WO (1) WO2008010527A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157385A (ja) * 1994-12-07 1996-06-18 Kirin Brewery Co Ltd 便通改善剤、腸粘膜増殖増強剤および経腸栄養剤
JP2002003388A (ja) * 2000-06-20 2002-01-09 Nof Corp 便秘解消剤組成物
JP2002226369A (ja) * 2001-01-30 2002-08-14 Otsuka Pharmaceut Co Ltd グルタミン含有経口組成物
JP2004224777A (ja) * 2003-01-27 2004-08-12 Hayashibara Biochem Lab Inc 抗便秘組成物
JP2005002098A (ja) * 2003-04-23 2005-01-06 Morinaga & Co Ltd 整腸作用を有する組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2524551B2 (ja) * 1992-02-28 1996-08-14 雪印乳業株式会社 グルタミン含量の高いペプチド組成物、その製造方法及び経腸栄養剤
JPH10194981A (ja) * 1997-01-09 1998-07-28 Keinzu Corp:Kk 便秘予防及び治療剤
KR101133944B1 (ko) * 2004-06-28 2012-04-13 아지노모토 가부시키가이샤 영양 조성물 및 소화관 기능 저하 예방?개선용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157385A (ja) * 1994-12-07 1996-06-18 Kirin Brewery Co Ltd 便通改善剤、腸粘膜増殖増強剤および経腸栄養剤
JP2002003388A (ja) * 2000-06-20 2002-01-09 Nof Corp 便秘解消剤組成物
JP2002226369A (ja) * 2001-01-30 2002-08-14 Otsuka Pharmaceut Co Ltd グルタミン含有経口組成物
JP2004224777A (ja) * 2003-01-27 2004-08-12 Hayashibara Biochem Lab Inc 抗便秘組成物
JP2005002098A (ja) * 2003-04-23 2005-01-06 Morinaga & Co Ltd 整腸作用を有する組成物

Also Published As

Publication number Publication date
JPWO2008010527A1 (ja) 2009-12-17
JP5412830B2 (ja) 2014-02-12

Similar Documents

Publication Publication Date Title
TWI478709B (zh) A useful oral or enteral composition for the recovery of bodily functions
WO2006054710A1 (fr) Agent visant a ameliorer le temps de transit maximum a travers le tube digestif, agent visant a ameliorer le temps de transit a travers le tube digestif et agent prophylactique pour le cancer du colon
KR20090086450A (ko) 기능성 소화관 장해 예방 또는 개선제 및 식품
WO2015105981A2 (fr) Essentialité conditionnelle de hmb
JP2005529980A (ja) 代謝ストレスを受けている哺乳動物における異化を治療または予防し、同化を促進する方法及び組成物
JPH1143438A (ja) カルシウム吸収亢進組成物
JP5383244B2 (ja) 癌患者の症状改善又は栄養状態の改善に適した栄養剤
WO2018095209A1 (fr) Composé multivitaminé stimulant l'appareil digestif
WO2011059075A1 (fr) Préparation riche en acide glutamique et riche en arginine
US20110060046A1 (en) Agent and food for preventing/improving functional digestive disorder
JP5527986B2 (ja) 医薬組成物
WO2008038771A1 (fr) Composition contenant de la glutamine destinée à augmenter le flux sanguin
JP3981991B2 (ja) 水性乳化栄養組成物及びその用途
JP5412830B2 (ja) 便通改善用組成物
EP2821069A1 (fr) Stimulateur de l'activité alimentaire et/ou de l'activité gastro-intestinale
JP2005350371A (ja) 肝障害者用栄養組成物
JP2010065013A (ja) 胃瘻患者に用いられる経腸栄養剤用の半固形化剤及び半固形化経腸栄養剤
JP4870957B2 (ja) 液体栄養食品用ゲル化食品
WO2017159741A1 (fr) Agent améliorant la condition physique
JP4721684B2 (ja) ダイフラクトースアンハイドライド含有経口組成物
TWI833705B (zh) 提升葡萄糖胺類之生物學利用率的方法
EP3389666A1 (fr) Compositions contenant de la 3'-o-glucuronide épicatéchine et procédés de fabrication et d'utilisation desdites compositions
JP6727051B2 (ja) 増粘剤、組成物キット及び組成物を増粘させる方法
EP3983076A1 (fr) Oligosaccharides de lait maternel et compositions de ceux-ci à utiliser dans la prévention, la gestion ou le traitement de symptômes liés à la migraine
TWI565418B (zh) Semi - solid nutrition for gastric stoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07790959

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008525888

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07790959

Country of ref document: EP

Kind code of ref document: A1